Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

Japanese patent issued to Santen for new agents for glaucoma

March 1, 2001

Statistically significant phase II results reported for INS-365 Ophthalmic

Feb. 28, 2001

Santen granted rights to develop and market lomerizine for ophthalmological indications

Feb. 27, 2001

Promising data reported for Visudyne in occult AMD and pathological myopia

Feb. 14, 2001

GenVec to apply PEDF technology to the treatment of blindness

Feb. 13, 2001

FDA issues approvable letter for Visudyne

Feb. 5, 2001

Clearance sought to begin clinical trials with INS-37217 Ophthalmic

Feb. 2, 2001

Clinical evaluation of Envision TD for DME and posterior uveitis continues

Jan. 26, 2001

New ROCK inhibitor with potential for the treatment of glaucoma licensed out by Welfide

Jan. 25, 2001

Antibacterial eyedrops to be jointly developed by SSP and InSite

Jan. 25, 2001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...